Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Praxis Precision Medicines is anticipated to report Q2 2025 earnings on August 12, with expected losses of ($3.40) per share and revenue of $0.16 million.
• Analysts forecast a negative net margin of 2,137.48% and a return on equity of -50.42% for the company, with forecasts of $-10 EPS for the current fiscal year.
• Several firms have given varying ratings on PRAX, leading to a consensus rating of "Moderate Buy" and a target price of $95.22.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) is expected to post its Q2 2025 & Study Result quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Praxis Precision Medicines to post earnings of ($3.40) per share and revenue of $0.16 million for the quarter.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($3.31) earnings per share for the quarter, beating analysts' consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative return on equity of 60.07% and a negative net margin of 2,137.48%. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

PRAX traded down $1.33 during midday trading on Thursday, hitting $47.27. The stock had a trading volume of 241,647 shares, compared to its average volume of 559,725. The company has a market cap of $995.03 million, a P/E ratio of -3.85 and a beta of 2.62. The business has a fifty day moving average of $47.96 and a 200 day moving average of $48.50. Praxis Precision Medicines has a 1 year low of $26.70 and a 1 year high of $91.83.

Institutional Trading of Praxis Precision Medicines

A hedge fund recently raised its stake in Praxis Precision Medicines stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 367.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,081 shares of the company's stock after buying an additional 68,466 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.43% of Praxis Precision Medicines worth $3,298,000 at the end of the most recent reporting period. Institutional investors own 67.84% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PRAX. Oppenheimer upped their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Chardan Capital reissued a "buy" rating and issued a $80.00 price target on shares of Praxis Precision Medicines in a research note on Tuesday, July 29th. Wedbush raised their price objective on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a research note on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a research note on Thursday, June 12th. Finally, HC Wainwright restated a "buy" rating and set a $115.00 target price (up from $105.00) on shares of Praxis Precision Medicines in a report on Tuesday. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $95.22.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.